ArticleLeukemia2014

Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.

Y Maesako et al.PubMed ↗Publisher ↗

No numbers read from the abstract.